News
Dealbreaker on MSN20h
BioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion Deal
After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback